Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Spondylitis, Ankylosing 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1Hand-Foot Syndrome 1Endometrial Neoplasms 1Colon Cancer Stage 1Bile Duct Neoplasms 1

Interventions

Cisplatin 51Gemcitabine 24Radiotherapy, Intensity-Modulated 21Docetaxel 20Fluorouracil 15camrelizumab 12Drug Therapy 11Radiotherapy 10toripalimab 8Chemoradiotherapy 8Capecitabine 8apatinib 7Induction Chemotherapy 7nimotuzumab 6endostar protein 6Endostatins 6sintilimab 5nedaplatin 5Bevacizumab 5fludarabine 4Cyclophosphamide 4spartalizumab 3fludarabine phosphate 3cisplatin-guanosine adduct 3SSRP1 protein, human 3Paclitaxel 3Injections 3Endoscopy 3tislelizumab 2Vitamin B 12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nasopharyngeal Carcinoma × Celecoxib × Clear all
NCT02537925 2015-09-02

The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma

Nanning Second People's Hospital

Phase 3 Unknown
120 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡